替罗非班治疗急性进展性脑梗死的临床疗效观察

Clinical Observation of Tirofiban in the Treatment of Acute Progressive Cerebral Infarction

目的探讨替罗非班治疗急性进展性脑梗死的临床疗效。方法选择2019年6月至2020年6月鹰潭市人民医院神经内科收治的80例急性进展性脑梗死患者,按随机数字表法分为两组,各40例。对照组给予氢氯吡格雷和阿司匹林治疗,观察组加用替罗非班治疗。比较两组临床疗效、凝血功能、血脂、神经功能、肝肾功能及不良反应。结果观察组临床疗效较对照组高。治疗后,观察组凝血酶时间、凝血酶原时间、活化部分凝血活酶时间高于对照组,D-二聚体低于对照组,美国国立卫生研究院卒中量表评分低于对照组,差异有统计学意义(P<0.05)。两组血脂指标、肝肾功能及不良反应比较,差异无统计学意义(P>0.05)。结论替罗非班可有效地改善急性进展性脑梗死患者的凝血功能,减轻其神经功能损伤,且对肝肾功能损害较小,安全可靠。

Objective To investigate the clinical efficacy of tirofiban in the treatment of acute progressive cerebral infarction.Methods 80 patients with acute progressive cerebral infarction admitted to Yingtan People's Hospital from June 2019 to June 2020 were selected and randomly divided into two groups,40 cases in each group.The control group was treated with clopidogrel and aspirin,and the observation group was treated with tirofiban based on the control group.The clinical efficacy,coagulation function,blood lipids,neurological function,liver and kidney function and adverse reactions were compared between the two groups.Results The clinical efficacy of the observation group was higher than that of the control group.After treatment,the thrombin time,prothrombin time,activated partial thromboplastin time of the observation group were higher than those of the control group,the D-Dimer was lower than that of the control group,and the National Institutes of Health Stroke Scale score was lower than that of the control group,with statistical difference(P<0.05).There was no statistical difference in blood lipid index,liver and kidney function and adverse reactions between the two groups(P>0.05).Conclusion Tirofiban has better effect in the treatment of patients with acute progressive cerebral infarction,can significantly improve the coagulation function and neurological function of patients,and has less damage to liver and kidney function,low incidence of adverse reactions,and good safety.